Most recent update: Sunday, April 29, 2018 - 14:56

You are here

News

09/01/18 - Research
EVTA and thrombotic complications
There was no statistical difference in successful closure rates when comparing radiofrequency (RFA) and endovenous laser (EVLA) ablation techniques, according to a large single centre experience with...
19/12/17 - Research
ATTRACT study
The results of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) study have revealed that clot busting drugs and medical devices do not improve...
04/12/17 - Research
Venous leg ulcers
Low dose aspirin does not increase healing of venous leg ulcers (VLU) when used in addition to effective compression, according to researchers from the University of Auckland, New Zealand. The study...
04/12/17 - Research
Thrombo-vascular complications
Researchers at Boston University School of Medicine (BUSM) have discovered a potential treatment target to prevent chronic kidney disease patients from developing thrombosis without causing bleeding...
04/12/17 - Research
Venous access ports
Cardiff Metropolitan University (CMU) has secured funding to support an interdisciplinary collaboration arising from the Welsh Crucible programme that looks at the design and development of an...
10/05/18 - Research
May-Thurner Syndrome
May-Thurner Syndrome (MTS) - sometimes inaccurately used in the literature to describe iliac vein compression - is more common in women with a ratio of at least 2:1 compared with men, according to a...
25/05/18 - Research
Venous leg ulcers
Early endovenous ablation of superficial venous reflux as an adjunct to compression therapy is associated with a shorter time to healing of venous leg ulcers than compression therapy alone, according...
10/05/18 - Research
Leg ulcer guidance
The Royal Society of Medicine’s Venous Forum (UK) has issued a guidance document for the ‘Management of patients with Leg Ulcers, to ensure that all patients with leg ulceration are offered the most...
10/05/18 - Research
Andexanet
The experimental drug andexanet was associated with control of serious bleeding in patients taking a common class of anticoagulants known as Factor Xa inhibitors, according to interim clinical trial...

Monthly archive